Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cryotherapy × Dermatologic × Clear all

Phase

Phase 4 4 Phase 3 3 Phase 2 3 Phase NA 2 Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 65 Nivolumab 48 Ipilimumab 36 Cyclophosphamide 33 aldesleukin 25 Interleukin-2 20 fludarabine 16 fludarabine phosphate 15 Temozolomide 15 trametinib 10 dabrafenib 10 Radiotherapy 10 Biopsy 10 avelumab 8 Bevacizumab 8 sargramostim 7 cemiplimab 7 Paclitaxel 7 Cisplatin 7 lenvatinib 6 Magnetic Resonance Spectroscopy 6 Fluorouracil 6 Dacarbazine 6 spartalizumab 5 poly ICLC 5 montanide ISA 51 5 Specimen Handling 5 Peripheral Blood Stem Cell Transplantation 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 epacadostat 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03949153 2025-10-01

CRIRIN

University Hospital, Strasbourg, France

Phase 1/2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡